Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C
Joshua A. Stern(University of California, Davis), Samantha P. Harris(University of Arizona), Joanna L. Kaplan(University of California, Davis), Kristina B. Kooiker(University of Washington), Victor N. Rivas(North Carolina State University), Sabine J. van Dijk(University of Arizona), Eric Ontiveros(Children’s Institute), Yu Ueda(North Carolina State University), Maureen S. Oldach
Cited by 11
Related Papers
Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes
|Journal of Molecular and Cellular Cardiology|2016|152
Physiological Mitochondrial Fragmentation Is a Normal Cardiac Adaptation to Increased Energy Demand
|Circulation Research|2017|143
Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment
|Aging Cell|2019|102
Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin
|Cell Reports|2016|94
β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
|Nature Communications|2019|90